MS-553 for returning or resistant chronic lymphocytic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental pill called MS-553 for people with CLL or SLL that has not responded to treatment or came back. The drug targets a protein that helps cancer cells grow, and the goal is to see if it can control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that is confirmed by a biopsy or other standard tests.
- Your CLL or SLL must need treatment right now, according to standard guidelines, or you need treatment to shrink the disease before a stem cell transplant.
- Your CLL/SLL must have returned after treatment or not responded to previous treatment.
- You cannot have CLL/SLL that has changed into a more aggressive lymphoma (like diffuse large B-cell lymphoma or Hodgkin lymphoma).
- You cannot have active and uncontrolled autoimmune low blood counts (like autoimmune hemolytic anemia or immune thrombocytopenia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This study tests two targeted oral medications, zanubrutinib and sonrotoclax, for people with CLL or SLL that has come back. The goal is to see if combining them can control the disease better and with fewer side effects than current options.
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
This trial tests a new pill combination for chronic lymphocytic leukemia (CLL) that has not been treated before. The drugs are designed to attack CLL cells in two different ways to try to improve outcomes.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
Hear when a new CLL (Chronic Lymphocytic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.